Amedisys (AMED) Tops Q2 EPS by 22c

Amedisys (NASDAQ: AMED) reported Q2 EPS of $1.00, $0.22 better than the analyst estimate of $0.78. Revenue for the quarter came in at $411.6 million versus the consensus estimate of $403.62 million.

GUIDANCE:

Amedisys sees FY2018 EPS of $3.32-$3.41, versus the consensus of $3.10. Amedisys sees FY2018 revenue of $1.63-1.65 million, versus the consensus of $1.63 million.

For earnings history and earnings-related data on Amedisys (AMED) click here.

You May Also Be Interested In

• Klarna shares tumble on weak full-year revenue guidance
• Klarna Group plc (KLAR) Tops Q2 EPS by 6c, Beats on Revenue; Offers FY26 Revenue Guidance
• Home Depot beats estimates, reaffirms fiscal 2026 guidance